Market Overview

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access


Gamida Cell, a leading cellular and immune therapeutics company, today
announced the appointments of Tzvi Palash as chief operating officer
(COO) and John D. Schick as vice president, market access.

Mr. Palash brings over 30 years of expertise in commercial operations in
the healthcare industry to this new role at Gamida Cell, where he will
be responsible for overseeing operational activities. Mr. Palash joins
Gamida Cell from Protalix Biotherapeutics, Inc., where, as COO, he led
all operational activities through the company's approval by the U.S.
Food and Drug Administration (FDA) of plant cell culture produced
protein product, Elelyso®. Prior to joining Protalix, Mr.
Palash served as a general manager at ColBar LifeScience Ltd, a
biomaterial company acquired by Johnson & Johnson, where he led the
planning, construction, scale-up and regulatory oversight of its
Israel-based manufacturing facility. He also successfully led FDA audits
for Evolence® and Ossix®, and was a member of the
Global Aesthetic Management Team within the Consumer Group of Johnson &
Johnson. Earlier in his career, Mr. Palash held operational roles at
Teva Pharmaceutical Industries and Interpham Laboratories.

Mr. Schick will lead the strategic planning and implementation of global
market access and reimbursement initiatives. He joins Gamida Cell from
Kite Pharma, where he served as senior director, payer relations, and
was responsible for the development and implementation of tactical
strategies to ensure appropriate access to cancer immunotherapy YESCARTA®.
Prior to joining Kite, Mr. Schick served as a director at Infinity
Pharmaceuticals, where he led the design, implementation and management
of trade, distribution and physician network functions to support
potential launch of the company's hematology/oncology candidate. Mr.
Schick has also held various roles at Onyx Pharmaceuticals, Otsuka
America Pharmaceutical and Allergan.

"We are delighted to welcome Tzvi and John to the Gamida Cell team,"
said Julian Adams, Ph.D., chairman and chief executive officer of Gamida
Cell. "Their unique experiences in operations and market access will be
strong assets to Gamida Cell as we continue to advance our clinical
programs in blood cancers and rare hematologic diseases."

About Gamida Cell
Gamida Cell is a clinical-stage
biopharmaceutical company leveraging its proprietary technology to
develop cell therapies that are designed to cure cancer and rare,
serious hematologic diseases. The company is developing a diverse
pipeline based on its nicotinamide-, or NAM, -based cell expansion
technology, addressing limitations of current cell therapies to provide
new treatment alternatives for patients. To learn more about Gamida
Cell, including current clinical studies, please visit
and on Twitter,
and Facebook.

View Comments and Join the Discussion!